Bladder Cancer: A Novel Multiplex ELISA Assay

What is the Purpose of this Study?

This study focuses on patients who have visible blood in their urine, which may be an early sign of bladder cancer. The purpose of the study is to determine whether an investigational laboratory test can detect bladder cancer in urine. To evaluate the test’s effectiveness, researchers will collect a sample of the participant’s urine, bladder tissue collected during a routine procedure (if available), and information from medical records.

Financial disclosure: Charles Rosser, MD, the person responsible for the conduct of this study, has a personal interest in the investigational test that is being used; he holds intellectual property rights for the test.


Eligibility

  • * Age 18 years or older
  • * Have documented or reported gross hematuria within 3 month of study enrollment
  • * Willing and able to give written informed consent
Show more

Where can I participate?

Cedars-Sinai Cancer at SOCC : Amy Oppenheim

More about this Clinical Trial

What is the full name of this clinical trial?

IIT2019-04-ROSSER-GH: A Novel Multiplex ELISA Assay for Evaluating Patient with gross hematuria for bladder cancer

Study Details
Disease Type/Condition

Bladder cancer detection, Urology

Principal Investigator

Furuya, Hideki

Co-Investigators

Charles Rosser, Hyung Kim, Timothy Daskivich

Age Group

Adult

Phase

III (Cancer Control)

IRB Number

Pro00057056

ClinicalTrials.gov ID

NCT03193528

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Amy Oppenheim

Phone
+1 310-423-3713
Email
amy.oppenheim@cshs.org
Study Detail
Disease Type/Condition

Bladder cancer detection, Urology

Principal Investigator

Furuya, Hideki

Age Group

Adult

Phase

III (Cancer Control)

IRB Number

IIT2019-04-ROSSER-GH

ClinicalTrials.gov ID

NCT03193528

Key Eligibility
ClinicalTrials.gov

Contact
Name

Amy Oppenheim

Phone
+1 310-423-3713
Email
amy.oppenheim@cshs.org